Brian Park, PharmD

Drug Information Specialist https://www.renalandurologynews.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Diabetic Nephropathy

Finerenone Gets Priority Review for Diabetic Kidney Disease

Brian Park, PharmD

January 18, 2021

The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.

Chronic Kidney Disease (CKD)

Sparsentan Granted Orphan Drug Status for IgA Nephropathy

Brian Park, PharmD

January 18, 2021

Sparsentan is an investigational small molecule candidate designed to selectively block the receptors of endothelin type A and angiotensin II type I, which are associated with kidney disease progression.

Prostate Cancer

Overall Survival Data Added to Nubeqa Prescribing Information

Brian Park, PharmD

January 12, 2021

Nubeqa, an androgen receptor inhibitor, was approved for the treatment of patients with nmCRPC based on data from the placebo-controlled phase 3 ARAMIS trial.

Men's Health Update

FDA: SARS-CoV-2 Mutations May Impact Molecular Tests

Brian Park, PharmD

January 11, 2021

The FDA is alerting clinical laboratory staff and health care providers regarding the risk of false negative results with any SARS-CoV-2 test if a mutation occurs in the part of the virus’ genome assessed by that test.

Prostate Cancer

Orgovyx Now Available for Advanced Prostate Cancer

Brian Park, PharmD

January 8, 2021

Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist.

Chronic Kidney Disease (CKD)

Dapagliflozin Under Review for Chronic Kidney Disease

Brian Park, PharmD

January 6, 2021

The FDA has granted Priority Review to dapagliflozin (Farxiga) for the treatment of new or worsening CKD.

Men's Health Update

FDA Authorizes First OTC Rapid Antigen Test for COVID-19

Brian Park, PharmD

December 16, 2020

The Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Ellume COVID-19 Home Test, the first over-the-counter (OTC) fully at-home diagnostic antigen test for coronavirus disease 2019 (COVID-19). The Ellume COVID-19 Home Test is a rapid, lateral flow antigen test developed with support from the National Institutes of Health’s Rapid Acceleration of…